APA (7th ed.) Citation

QQ, N., ZZ, F., BY, M., X, Z., HD, W., P, L., . . . V, L. (2025). Perillaldehyde targeting PARP1 to inhibit TRPM2-CaMKII/CaN signal transduction in diabetic cardiomyopathy. International immunopharmacology, 150, 114291. https://doi.org/10.1016/j.intimp.2025.114291

Chicago Style (17th ed.) Citation

QQ, Niu, et al. "Perillaldehyde Targeting PARP1 to Inhibit TRPM2-CaMKII/CaN Signal Transduction in Diabetic Cardiomyopathy." International Immunopharmacology 150 (2025): 114291. https://doi.org/10.1016/j.intimp.2025.114291.

MLA (9th ed.) Citation

QQ, Niu, et al. "Perillaldehyde Targeting PARP1 to Inhibit TRPM2-CaMKII/CaN Signal Transduction in Diabetic Cardiomyopathy." International Immunopharmacology, vol. 150, 2025, p. 114291, https://doi.org/10.1016/j.intimp.2025.114291.